Featured Research

from universities, journals, and other organizations

Varying Combinations Of Antiviral Drugs May Effectively Treat Chronic Hepatitis Virus Infection In Woodchucks

Date:
October 20, 2008
Source:
American Society for Microbiology
Summary:
Oral administration of various combined and independent antiviral drug therapies may effectively treat chronic hepatitis B virus (HBV) infection in woodchucks, a well-characterized mammalian model for research with human implications, and provide an alternative strategy for managing drug resistance.

Oral administration of various combined and independent antiviral drug therapies may effectively treat chronic hepatitis B virus (HBV) infection in woodchucks, a well-characterized mammalian model for research with human implications, and provide an alternative strategy for managing drug resistance.

The researchers from Cornell University, Ithaca, New York; Gilead Sciences, Durham, North Carolina; and Georgetown University Medical Center, Washington, DC report their findings in the October 2008 issue of the journal Antimicrobial Agents and Chemotherapy.

Chronic infection with HBV is responsible for 1.2 million annual deaths worldwide. Statistics also show that 2 billion people currently or previously suffered from infection while 350 million people are chronic carriers of HBV and are at risk of developing chronic hepatitis, hepatic cirrhosis, and hepatocellular carcinoma. Preventative vaccines are currently offered, however, side effects and drug resistance are limiting the efficacy of available treatment therapies.

In the study researchers evaluated the antiviral effects of orally administered adefovir dipivoxil (ADV) or tenofovir disoproxil fumarate (TDF) alone or in combination with lamivudine (3TC) or emtricitabine (FTC) in woodchucks with chronic hepatitis virus infection. Initial results showed once daily treatment for 48 weeks with ADV plus 3TC or TDF plus FTC greatly reduced viral levels from those pretreatment. Additional treatment with TDF plus 3TC, ADV alone, ADV plus FTC, TDF alone, 3TC alone, and FTC alone showed pronounced declines in viral levels in all groups. Following drug withdrawal most woodchucks displayed renewed hepatitis virus replication, but some did experience sustained effects. Lastly, no toxicity was observed following administration of any of the drugs or drug combinations.

"In conclusion, the oral administration of 3TC, FTC, ADV, and TDF alone and in combination was safe and effective in the woodchuck model of HBV infection," say the researchers.


Story Source:

The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. Menne, S.D. Bulter, A.L. George, I.A. Tochkov, Y. Zhu, S. Xiong, J.L. Gerin, P.J. Cote, B.C. Tennant. Antiviral Effects of Lamivudine, Emtricitabine, Adefovir Dipivoxil, and Tenofovir Disoproxil Fumarate Administered Orally Alone and in Combination to Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. Antimicrobial Agents and Chemotherapy, 2008; 52 (10): 3617 DOI: 10.1128/AAC.00654-08

Cite This Page:

American Society for Microbiology. "Varying Combinations Of Antiviral Drugs May Effectively Treat Chronic Hepatitis Virus Infection In Woodchucks." ScienceDaily. ScienceDaily, 20 October 2008. <www.sciencedaily.com/releases/2008/10/081016133509.htm>.
American Society for Microbiology. (2008, October 20). Varying Combinations Of Antiviral Drugs May Effectively Treat Chronic Hepatitis Virus Infection In Woodchucks. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2008/10/081016133509.htm
American Society for Microbiology. "Varying Combinations Of Antiviral Drugs May Effectively Treat Chronic Hepatitis Virus Infection In Woodchucks." ScienceDaily. www.sciencedaily.com/releases/2008/10/081016133509.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins